Genomic and Epigenomic Landscape in Meningioma

Neurosurgery Clinics of North America

Volumn 27, Issue 2, 2016, Pages 167-179

  Bi, Wenya Linda ^a,b   Mei, Yu ^a   Agarwalla, Pankaj K ^b   Beroukhim, Rameen ^b   Dunn, Ian F ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epigenetics; Genomics; Meningioma; Molecular taxonomy; Precision medicine

Indexed keywords

KRUPPEL LIKE FACTOR 4; SMOOTHENED PROTEIN;

AKT1 GENE; CARCINOGENESIS; CHROMOSOME; COPY NUMBER VARIATION; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENOMICS; HUMAN; KLF4 GENE; MENINGIOMA; MOLECULAR GENETICS; NF2 GENE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SMO GENE; TRAF7 GENE; TUMOR CLASSIFICATION; ANIMAL; CHROMOSOME ABERRATION; GENETIC EPIGENESIS; GENETICS; MUTATION;

ANIMALS; CHROMOSOME ABERRATIONS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MUTATION;

EID: 84961245796     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2015.11.009     Document Type: Review

References (92)

1. Ostrom Q.T., Gittleman H., Farah P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 2013, 15(Suppl 2):ii1-ii56.
2. Herscovici Z., Rappaport Z., Sulkes J., et al. Natural history of conservatively treated meningiomas. Neurology 2004, 63(6):1133-1134.
3. Louis D.N., Ohgaki H., Wiestler O.D., et al. WHO classification of tumours of the central nervous system 2007, IARC Press, Lyon (France). 4th edition.
4. Tanzler E., Morris C.G., Kirwan J.M., et al. Outcomes of WHO grade I meningiomas receiving definitive or postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2011, 79(2):508-513.
5. van Alkemade H., de Leau M., Dieleman E.M., et al. Impaired survival and long-term neurological problems in benign meningioma. Neuro Oncol 2012, 14(5):658-666.
6. Rogers L., Barani I., Chamberlain M., et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg 2015, 122(1):4-23.
7. Palma L., Celli P., Franco C., et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. J Neurosurg 1997, 86(5):793-800.
8. Durand A., Labrousse F., Jouvet A., et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol 2009, 95(3):367-375.
9. Sun S.Q., Kim A.H., Cai C., et al. Management of atypical cranial meningiomas, part 1: predictors of recurrence and the role of adjuvant radiation after gross total resection. Neurosurgery 2014, 75(4):347-354. [discussion: 354-5; quiz: 355].
10. Sun S.Q., Cai C., Murphy R.K., et al. Management of atypical cranial meningiomas, part 2: predictors of progression and the role of adjuvant radiation after subtotal resection. Neurosurgery 2014, 75(4):356-363. [discussion: 363].
11. Palma L., Celli P., Franco C., et al. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases. Neurosurg Focus 1997, 2(4):e3.
12. Witt H., Mack S.C., Ryzhova M., et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011, 20(2):143-157.
13. Northcott P.A., Korshunov A., Pfister S.M., et al. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012, 8(6):340-351.
14. Brennan C.W., Verhaak R.G., McKenna A., et al. The somatic genomic landscape of glioblastoma. Cell 2013, 155(2):462-477.
15. Sosman J.A., Kim K.B., Schuchter L., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366(8):707-714.
16. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344(14):1031-1037.
17. Brastianos P.K., Horowitz P.M., Santagata S., et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013, 45(3):285-289.
18. Clark V.E., Erson-Omay E.Z., Serin A., et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013, 339(6123):1077-1080.
19. Bi W.L., Abedalthagafi M., Horowitz P., et al. Genomic landscape of intracranial meningiomas. J Neurosurg 2016.
20. He S., Pham M.H., Pease M., et al. A review of epigenetic and gene expression alterations associated with intracranial meningiomas. Neurosurg Focus 2013, 35(6):E5.
21. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3(6):415-428.
22. Bello M.J., Aminoso C., Lopez-Marin I., et al. DNA methylation of multiple promoter-associated CpG islands in meningiomas: relationship with the allelic status at 1p and 22q. Acta Neuropathol 2004, 108(5):413-421.
23. Das P.M., Singal R. DNA methylation and cancer. J Clin Oncol 2004, 22(22):4632-4642.
24. McDermott U., Downing J.R., Stratton M.R. Genomics and the continuum of cancer care. N Engl J Med 2011, 364(4):340-350.
25. Cheishvili D., Boureau L., Szyf M. DNA demethylation and invasive cancer: implications for therapeutics. Br J Pharmacol 2015, 172(11):2705-2715.
26. Fontaine B., Rouleau G.A., Seizinger B.R., et al. Molecular genetics of neurofibromatosis 2 and related tumors (acoustic neuroma and meningioma). Ann N Y Acad Sci 1991, 615:338-343.
27. Ruttledge M.H., Sarrazin J., Rangaratnam S., et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet 1994, 6(2):180-184.
28. Perry A., Scheithauer B.W., Stafford S.L., et al. Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 1999, 85(9):2046-2056.
29. Kalamarides M., Niwa-Kawakita M., Leblois H., et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 2002, 16(9):1060-1065.
30. Kalamarides M., Stemmer-Rachamimov A.O., Niwa-Kawakita M., et al. Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011, 30(20):2333-2344.
31. Reuss D.E., Piro R.M., Jones D.T., et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013, 125(3):351-358.
32. Takahashi K., Tanabe K., Ohnuki M., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
33. Sahm F., Bissel J., Koelsche C., et al. AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 2013, 126(5):757-762.
34. Bleeker F.E., Felicioni L., Buttitta F., et al. AKT1(E17K) in human solid tumours. Oncogene 2008, 27(42):5648-5650.
35. Reifenberger J., Wolter M., Weber R.G., et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998, 58(9):1798-1803.
36. Jones D.T., Jager N., Kool M., et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 2012, 488(7409):100-105.
37. Sekulic A., Migden M.R., Oro A.E., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012, 366(23):2171-2179.
38. Perry A., Louis D.N., Scheithauer B.W., et al. Meningiomas. WHO classification of tumours of the central nervous system 2007, 164-172. IARC, Lyon (France). 4th edition. D.N. Louis, H. Ohgaki, O.D. Wiestler (Eds.).
39. Abedalthagafi M.S., Merrill P.H., Bi W.L., et al. Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. Oncotarget 2014, 5(21):10596-10606.
40. Cai D.X., Banerjee R., Scheithauer B.W., et al. Chromosome 1p and 14q FISH analysis in clinicopathologic subsets of meningioma: diagnostic and prognostic implications. J Neuropathol Exp Neurol 2001, 60(6):628-636.
41. Buschges R., Ichimura K., Weber R.G., et al. Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002, 12(2):145-153.
42. Lomas J., Aminoso C., Gonzalez-Gomez P., et al. Methylation status of TP73 in meningiomas. Cancer Genet Cytogenet 2004, 148(2):148-151.
43. Lusis E.A., Watson M.A., Chicoine M.R., et al. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005, 65(16):7121-7126.
44. Liu Y., Pang J.C., Dong S., et al. Aberrant CpG island hypermethylation profile is associated with atypical and anaplastic meningiomas. Hum Pathol 2005, 36(4):416-425.
45. Carling T., Kim K.C., Yang X.H., et al. A histone methyltransferase is required for maximal response to female sex hormones. Mol Cell Biol 2004, 24(16):7032-7042.
46. Chadwick R.B., Jiang G.L., Bennington G.A., et al. Candidate tumor suppressor RIZ is frequently involved in colorectal carcinogenesis. Proc Natl Acad Sci U S A 2000, 97(6):2662-2667.
47. He L., Yu J.X., Liu L., et al. RIZ1, but not the alternative RIZ2 product of the same gene, is underexpressed in breast cancer, and forced RIZ1 expression causes G2-M cell cycle arrest and/or apoptosis. Cancer Res 1998, 58(19):4238-4244.
48. Jiang G., Liu L., Buyse I.M., et al. Decreased RIZ1 expression but not RIZ2 in hepatoma and suppression of hepatoma tumorigenicity by RIZ1. Int J Cancer 1999, 83(4):541-546.
49. Liu Z.Y., Wang J.Y., Liu H.H., et al. Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human malignant meningiomas. Oncogene 2013, 32(10):1216-1222.
50. Ding M.H., Wang Z., Jiang L., et al. The transducible TAT-RIZ1-PR protein exerts histone methyltransferase activity and tumor-suppressive functions in human malignant meningiomas. Biomaterials 2015, 56:165-178.
51. Rauch T., Wang Z., Zhang X., et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci U S A 2007, 104(13):5527-5532.
52. Wu Q., Lothe R.A., Ahlquist T., et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer 2007, 6:45.
53. Kishida Y., Natsume A., Kondo Y., et al. Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis 2012, 33(2):436-441.
54. Ando H., Natsume A., Senga T., et al. Peptide-based inhibition of the HOXA9/PBX interaction retards the growth of human meningioma. Cancer Chemother Pharmacol 2014, 73(1):53-60.
55. Jun P., Hong C., Lal A., et al. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol 2009, 11(4):414-422.
56. Moniz S., Verissimo F., Matos P., et al. Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. Oncogene 2007, 26(41):6071-6081.
57. Gao F., Shi L., Russin J., et al. DNA methylation in the malignant transformation of meningiomas. PLoS One 2013, 8(1):e54114.
58. Smith M.J., O'Sullivan J., Bhaskar S.S., et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 2013, 45(3):295-298.
59. Smith M.J., Wallace A.J., Bennett C., et al. Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 2014, 234(4):436-440.
60. Kros J., de Greve K., van Tilborg A., et al. NF2 status of meningiomas is associated with tumour localization and histology. J Pathol 2001, 194(3):367-372.
61. Di Vinci A., Brigati C., Casciano I., et al. HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Transl Res 2012, 160(5):355-362.
62. Barski D., Wolter M., Reifenberger G., et al. Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2010, 20(3):623-631.
63. Nakane Y., Natsume A., Wakabayashi T., et al. Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg 2007, 107(2):398-404.
64. Lee J.Y., Finkelstein S., Hamilton R.L., et al. Loss of heterozygosity analysis of benign, atypical, and anaplastic meningiomas. Neurosurgery 2004, 55(5):1163-1173.
65. Lamszus K., Kluwe L., Matschke J., et al. Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 1999, 110(2):103-110.
66. Aizer A.A., Abedalthagafi M., Bi W.L., et al. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol 2016, 18(2):269-274.
67. Langford L.A., Piatyszek M.A., Xu R., et al. Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 1997, 28(4):416-420.
68. Sawyer J.R., Husain M., Pravdenkova S., et al. A role for telomeric and centromeric instability in the progression of chromosome aberrations in meningioma patients. Cancer 2000, 88(2):440-453.
69. Chen H.J., Liang C.L., Lu K., et al. Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 2000, 89(10):2092-2098.
70. Simon M., Park T.W., Leuenroth S., et al. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression. J Neurosurg 2000, 92(5):832-840.
71. Leuraud P., Dezamis E., Aguirre-Cruz L., et al. Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 2004, 100(2):303-309.
72. Goutagny S., Nault J.C., Mallet M., et al. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol 2014, 24(2):184-189.
73. Zhi F., Zhou G., Wang S., et al. A microRNA expression signature predicts meningioma recurrence. Int J Cancer 2013, 132(1):128-136.
74. Melino G., De Laurenzi V., Vousden K.H. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2002, 2(8):605-615.
75. Zhang X., Gejman R., Mahta A., et al. Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res 2010, 70(6):2350-2358.
76. Lu Z., Lam K.S., Wang N., et al. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells. Oncogene 2006, 25(20):2920-2930.
77. Cuevas I.C., Slocum A.L., Jun P., et al. Meningioma transcript profiles reveal deregulated Notch signaling pathway. Cancer Res 2005, 65(12):5070-5075.
78. Keller A., Ludwig N., Backes C., et al. Genome wide expression profiling identifies specific deregulated pathways in meningioma. Int J Cancer 2009, 124(2):346-351.
79. Larijani L., Madjd Z., Samadikuchaksaraei A., et al. Methylation of O6-methyl guanine methyltransferase gene promoter in meningiomas-comparison between tumor grades I, II, and III. Asian Pac J Cancer Prev 2014, 15(1):33-38.
80. Saydam O., Shen Y., Wurdinger T., et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009, 29(21):5923-5940.
81. Panetti T.S., Chen H., Misenheimer T.M., et al. Endothelial cell mitogenesis induced by LPA: inhibition by thrombospondin-1 and thrombospondin-2. J Lab Clin Med 1997, 129(2):208-216.
82. Ando H., Natsume A., Iwami K., et al. A hypoxia-inducible factor (HIF)-3alpha splicing variant, HIF-3alpha4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3alpha4. Biochem Biophys Res Commun 2013, 433(1):139-144.
83. Vengoechea J., Sloan A.E., Chen Y., et al. Methylation markers of malignant potential in meningiomas. J Neurosurg 2013, 119(4):899-906.
84. Kandenwein J.A., Park-Simon T.W., Schramm J., et al. uPA/PAI-1 expression and uPA promoter methylation in meningiomas. J Neurooncol 2011, 103(3):533-539.
85. Velpula K.K., Gogineni V.R., Nalla A.K., et al. Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells. Neoplasia 2013, 15(2):192-203.
86. Nordqvist A.C., Peyrard M., Pettersson H., et al. A high ratio of insulin-like growth factor II/insulin-like growth factor binding protein 2 messenger RNA as a marker for anaplasia in meningiomas. Cancer Res 1997, 57(13):2611-2614.
87. Wrobel G., Roerig P., Kokocinski F., et al. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005, 114(2):249-256.
88. Ioannidis P., Mahaira L.G., Perez S.A., et al. CRD-BP/IMP1 expression characterizes cord blood CD34+ stem cells and affects c-myc and IGF-II expression in MCF-7 cancer cells. J Biol Chem 2005, 280(20):20086-20093.
89. Kliese N., Gobrecht P., Pachow D., et al. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 2013, 32(39):4712-4720.
90. Perez-Magan E., Campos-Martin Y., Mur P., et al. Genetic alterations associated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol 2012, 71(10):882-893.
91. Perez-Magan E., Rodriguez de Lope A., Ribalta T., et al. Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol 2010, 12(12):1278-1290.
92. Linsler S., Kraemer D., Driess C., et al. Molecular biological determinations of meningioma progression and recurrence. PLoS One 2014, 9(4):e94987.